Skip to main content

Advertisement

SpringerLink
Log in

Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach

  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

Tocilizumab is a recombinant humanized antihuman interleukin-6 receptor monoclonal antibody, which inhibits binding of IL-6 to its soluble (sIL-6R) and membrane-expressed (mIL-6R) receptors. The work investigated whether the observed decline in peripheral neutrophil and platelet counts after tocilizumab administration can be directly explained by tocilizumab IL-6R blockade, thus demonstrating the mechanism of tocilizumab action. Tocilizumab and total sIL-6R concentrations, neutrophil and platelet counts from 4 phase 3 studies in rheumatoid arthritis patients were available. Patients received 4 or 8 mg/kg tocilizumab intravenous infusions every 4 weeks for a total of 6 doses. A population approach was applied to describe the relationship between tocilizumab and sIL-6R concentrations and subsequent changes in neutrophil and platelet counts. Following tocilizumab administration, concentrations of total sIL-6R increased, while neutrophil and platelet counts declined. These changes were transient, with counts returning to their respective baseline levels soon after tocilizumab is eliminated from the body. Tocilizumab concentrations were described by a two compartment model with parallel linear and Michaelis–Menten elimination. The quasi-steady-state target-mediated drug disposition model described tocilizumab relationships to total sIL-6R, which allowed computation of unobserved unbound sIL-6R concentrations. The neutrophil counts were described as a direct function of unbound sIL-6R concentrations. The platelet counts were described by the transit-compartment life-span model with inhibition of production that depended on the unbound sIL-6R concentrations. Thus, the observed changes in sIL-6R, neutrophil, and platelet data are consistent with the tocilizumab mechanism of action and can be fully explained by tocilizumab binding to sIL-6R and mIL-6R.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Fonseca JE, Santos MJ, Canhao H, Choy E (2009) Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 8:538–542

    Article  PubMed  CAS  Google Scholar 

  2. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets 11:613–624

    Article  PubMed  CAS  Google Scholar 

  3. Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC, Rose-John S (1993) The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23:473–480

    Article  PubMed  CAS  Google Scholar 

  4. Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, Matsumoto A, Yamamoto M, Yamamoto N (1994) Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol 24:1945–1948

    Article  PubMed  CAS  Google Scholar 

  5. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y (2010) Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 77:201–205

    Article  PubMed  Google Scholar 

  6. Madhok R, Crilly A, Watson J, Capell HA (1993) Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52:232–234

    Article  PubMed  CAS  Google Scholar 

  7. Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F (1993) Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 13:45–51

    Article  PubMed  CAS  Google Scholar 

  8. Emery P, Keystone E, Tony HP, Cantagrel A, van VR, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523

    Article  PubMed  CAS  Google Scholar 

  9. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968–2980

    Article  PubMed  CAS  Google Scholar 

  10. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997

    Article  PubMed  CAS  Google Scholar 

  11. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88–96

    Article  PubMed  CAS  Google Scholar 

  12. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J (2010) Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 32(9):1597

    Article  PubMed  CAS  Google Scholar 

  13. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248–252

    Article  PubMed  CAS  Google Scholar 

  14. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532

    Article  PubMed  CAS  Google Scholar 

  15. Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn 36:341–351

    Article  PubMed  Google Scholar 

  16. Gibiansky L, Gibiansky E (2010) Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 37:323–346

    Article  PubMed  CAS  Google Scholar 

  17. Suwa T, Hogg JC, English D, Van Eeden SF (2000) Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol 279:H2954–H2960

    PubMed  CAS  Google Scholar 

  18. Nakahata T, Yasukawa K. Method for increasing platelets by administering soluble interleukin-6R receptor. Stem Cell Institute. February 22, 2000; Available at: http://www.cellmedicine.com/research/patents/differentiation/us6028050/

  19. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34:1158–1163

    Article  PubMed  Google Scholar 

  20. Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589–1596

    Article  PubMed  CAS  Google Scholar 

  21. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573–591

    Article  PubMed  CAS  Google Scholar 

  22. Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 5:803–812

    Article  PubMed  CAS  Google Scholar 

  23. Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37:25–47

    Article  PubMed  CAS  Google Scholar 

  24. Gibiansky L, Gibiansky E (2009) Mechanistic interpretation of indirect-response models for drugs with target-mediated disposition. American Conference on Pharmacometrics; October 4–7, 2009

  25. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–4721

    Article  PubMed  Google Scholar 

  26. Joerger M, Huitema AD, Richel DJ, Dittrich C, Pavlidis N, Briasoulis E, Vermorken JB, Strocchi E, Martoni A, Sorio R, Sleeboom HP, Izquierdo MA, Jodrell DI, Calvert H, Boddy AV, Hollema H, Fety R, Van d V, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH, Twelves C, Beijnen JH, Schellens JH (2007) Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 13:6410–6418

    Article  PubMed  CAS  Google Scholar 

  27. Beal SL, Sheiner LB, Boeckmann AJ (2007) NONMEM Users Guide. Icon Development Solutions, Ellicott

    Google Scholar 

  28. Beal S, Sheiner L (2006) NONMEM users guides: part I–VIII. University of California at San Francisco, San Francisco

    Google Scholar 

  29. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17–20

    Article  PubMed  CAS  Google Scholar 

  30. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171–192

    Article  PubMed  CAS  Google Scholar 

  31. Wang DW, Zhang S (2011) Standardized visual predictive check versus visual predictive check for model evaluation. J Clin Pharmacol, doi: 10.1177/0091270010390040

  32. Mentre F, Escolano S (2006) Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn 33:345–367

    Article  PubMed  Google Scholar 

  33. Brendel K, Comets E, Laffont C, Laveille C, Mentre F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:2036–2049

    Article  PubMed  CAS  Google Scholar 

  34. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5(12):1731–1740

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. QuantPharm LLC, 49 Flints Grove Drive, North Potomac, MD, 20878, USA

    Leonid Gibiansky

  2. F Hoffman-La Roche Ltd, Pharma Research and Early Development (pRED) and Translational Research Sciences (TRS), Nutley, NJ, USA

    Nicolas Frey

Authors
  1. Leonid Gibiansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Frey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonid Gibiansky.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 2121 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibiansky, L., Frey, N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. J Pharmacokinet Pharmacodyn 39, 5–16 (2012). https://doi.org/10.1007/s10928-011-9227-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-011-9227-z

Keywords

Search

Navigation